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hrelin is an acyl-peptide gastric hormone acting on
the pituitary and hypothalamus to stimulate growth
hormone (GH) release, adiposity, and appetite.
Ghrelin endocrine activities are entirely dependent on its
acylation and are mediated by GH secretagogue (GHS)
receptor (GHSR)-1a, a G protein–coupled receptor mostly
expressed in the pituitary and hypothalamus, previously
identiﬁed as the receptor for a group of synthetic molecules
featuring GH secretagogue (GHS) activity. Des-acyl ghrelin,
which is far more abundant than ghrelin, does not bind
GHSR-1a, is devoid of any endocrine activity, and its
function is currently unknown. Ghrelin, which is expressed
in heart, albeit at a much lower level than in the stomach,
also exerts a cardio protective effect through an unknown
mechanism, independent of GH release. Here we show that
G
 
both ghrelin and des-acyl ghrelin inhibit apoptosis of primary
adult and H9c2 cardiomyocytes and endothelial cells in
vitro through activation of extracellular signal–regulated
kinase-1/2 and Akt serine kinases. In addition, ghrelin and
des-acyl ghrelin recognize common high afﬁnity binding
sites on H9c2 cardiomyocytes, which do not express
GHSR-1a. Finally, both MK-0677 and hexarelin, a non-
peptidyl and a peptidyl synthetic GHS, respectively, recognize
the common ghrelin and des-acyl ghrelin binding sites,
inhibit cell death, and activate MAPK and Akt.
These ﬁndings provide the ﬁrst evidence that, indepen-
 
dent of its acylation, ghrelin gene product may act as
a survival factor directly on the cardiovascular system
through binding to a novel, yet to be identiﬁed receptor,
which is distinct from GHSR-1a.
 
Introduction
 
Ghrelin is a newly discovered hormone, which induces the
release of growth hormone (GH)* and stimulates food intake
and adiposity (Kojima et al., 1999; Tschop et al., 2000;
Bowers, 2001; Inu, 2001; Nakazato et al., 2001). Although
ghrelin is essentially a gastric hormone, it is expressed
ubiquitously, although at low level (Gnanapavan et al.,
2002). Endocrine activities of ghrelin are mediated by GH
secretagogue (GHS) receptor (GHSR)-1a, a G protein–coupled
receptor mainly expressed in the pituitary and hypothalamus,
identified previously as the receptor for GH secretagogues
(GHSs), a group of synthetic molecules endowed with
strong GH release activity (Howard et al., 1996). Ghrelin is
a 28 amino acid acyl-peptide esterified with octanoic acid on
Ser 3. Acylation of ghrelin is required for GHSR-1a activation,
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whereas des-acyl ghrelin, which is far more abundant than
ghrelin (Hosoda et al., 2000), does not bind GHSR-1a and
is devoid of any endocrine activity (Kojima et al., 1999;
Muccioli et al., 2002; Torsello et al., 2002). The function of
des-acyl ghrelin is currently unknown.
Recent evidence indicates that ghrelin and synthetic
GHS feature a variety of cardiovascular activities, including
increase of myocardial contractility (Bisi et al., 1999; Na-
gaya et al., 2001a), vasodilatation (Okumura et al., 2002),
and protection from myocardial infarction-induced heart
failure in vivo (Locatelli et al., 1999; Tivesten et al., 2000;
King et al., 2001; Nagaya et al., 2001b). Some indirect evi-
dence suggests that ghrelin and GHS cardioprotective ac-
tivity is independent from GH secretion (Locatelli et al.,
1999; Tivesten et al., 2000). In addition, ghrelin receptor,
GHSR-1a, is expressed in the myocardium (Gnanapavan et
al., 2002), and both ghrelin and peptidyl GHS recognize
high affinity binding sites in the heart (Papotti et al., 2000;
Bodart et al., 2002; Katugampola et al., 2001). However,
the cellular and molecular mechanisms underlying ghrelin
and synthetic GHS cardioprotective activities have not
been investigated.
Based on these observations, we raised the hypothesis that
ghrelin may directly prevent cell death of cultured cardiomyo-
cytes and/or endothelial cells in vitro through activation of
a specific receptor expressed in these cells. The data reported
here support and extend such hypothesis, providing the first
evidence that both ghrelin and des-acyl ghrelin inhibit apop-
tosis of cardiomyocytes and endothelial cells through activa-
tion of a survival intracellular signaling pathway. In addi-
tion, these data indicate that a novel, yet to be identified
receptor, distinct from GHSR-1a, mediates ghrelin and des-
acyl ghrelin antiapoptotic activity, suggesting a novel role for
the ghrelin gene product independent of its acylation.
 
Results
 
Ghrelin inhibits doxorubicin-induced cell death in vitro
 
To investigate whether ghrelin may act as survival factor for
cardiovascular cells, we have treated H9c2 cardiomyocytes
with doxorubicin, which induces apoptotic cell death of car-
diomyocytes both in vitro and in vivo (Arola et al., 2000;
Wu et al., 2000). After 24 h of treatment, 1 
 
 
 
M doxorubi-
cin induced cell death of H9c2 cardiomyocytes as observed
by phase–contrast microscopy (Fig. 1 A). Dying cells be-
came light refractive and detached off the plate. However, in
the presence of a saturating concentration of ghrelin doxoru-
bicin-treated H9c2 cells maintained their morphology and
were still attached to the plate. In the absence of doxorubi-
cin, ghrelin did not affect cell morphology. Ghrelin cytopro-
tective activity was also assayed by measuring cell viability of
H9c2 cardiomyocytes. After 24 h of treatment with doxoru-
bicin, 50% of the cells were not viable as measured by the
3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay. However, doxorubicin-induced cell
death was almost completely abolished in the presence of a
saturating concentration of ghrelin (Fig. 1 B). The cytopro-
tective activity of ghrelin was concentration dependent, 0.1
nM being the lowest active concentration (Fig. 1
 
 
 
C). Similar
results were obtained when cell viability was measured as loss
of membrane impermeability. Upon 48 h of treatment, doxo-
rubicin induced lactate dehydrogenase (LDH) release in the
medium, which was completely prevented in the presence of
a saturating concentration of ghrelin (Fig. 1 D). Similar re-
sults were obtained in PAE endothelial cells (unpublished
data). Ghrelin alone did not affect cell survival of H9c2 car-
diomyocytes as measured by either MTT or the release of
LDH. Thus, these data provide the first indication that
ghrelin acts directly on cardiomyocytes to inhibit experi-
mentally induced cell death.
Figure 1. Ghrelin protects H9c2 cardiomyocytes from doxorubicin-induced cell death. H9c2 cardiomyocytes were treated with 1  M 
doxorubicin (grey bar) in the presence or absence of 1  M ghrelin. (A) Phase–contrast images (200 ; bar, 0.1 mm) after 24 h of treatment: 
untreated (a), ghrelin (b), doxorubicin (c), and doxorubicin   ghrelin (d). (B) Cell death measured by MTT assay after 24 h of treatment is 
expressed as the percentage of cell death. Values are the mean   SE of eight samples (*t test, P   0.01). (C) Dose response of ghrelin in MTT 
cell death assay after 24 h of treatment. Values are the mean   SE of eight samples. (D) Cell death measured by LDH release after 48 h of 
treatment. Values are the mean   SE of eight samples (*t test, P   0.01). 
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Ghrelin prevents apoptosis induced in vitro by both 
FAS activation and serum starvation
 
Apoptotic cell death of cardiomyocytes occurs during the
development of heart failure, whereas up-regulation of myo-
cardial expression of FAS correlates with cell death of car-
diomyocytes in ischemic-dilated and doxorubicin-induced
cardiomyopathies (Yamamura et al., 1999; Jeremias et al.,
2000; Nakamura et al., 2000). Activation of FAS receptor
stimulates apoptosis of terminally differentiated adult car-
diomyocytes both in vitro and in vivo (Takemura et al., 2001;
Hayakawa et al., 2002). In addition, the inhibition of apop-
tosis of cardiomyocytes by survival factors has been shown to
prevent cardiac heart failure (Parrizas et al., 1997). Here we
report that ghrelin treatment of primary adult cardiomyo-
cytes prevented apoptosis stimulated by anti-FAS agonist
antibodies (Fig. 2 A) in a concentration-dependent manner.
Apoptosis was measured as nucleosomal DNA fragmenta-
tion determined by FACS
 
®
 
 analysis.
In addition, we have assayed ghrelin’s ability to prevent
apoptosis induced by serum withdrawal in H9c2 and PAE
cells. Apoptosis was measured by externalization of phos-
phatidylserine, an early apoptotic event. Both H9c2 car-
diomyocytes and PAE cells underwent apoptosis after 48 h of
serum withdrawal. However, a saturating concentration of
ghrelin prevented apoptosis induced by the absence of serum
(Fig. 2, B and C). Thus, these data strongly indicate that
ghrelin acts as a survival factor in cardiomyocytes and endo-
thelial cells by inhibiting apoptosis induced through different
stimuli.
 
Ghrelin inhibits apoptosis by activation of 
antiapoptotic intracellular signaling pathways
 
To provide further biochemical evidence supporting the hy-
pothesis that ghrelin may act as a survival factor, we have in-
vestigated ghrelin’s ability to stimulate intracellular signaling
pathways leading to inhibition of apoptosis. Survival factors,
such as insulin growth factor-1 (IGF-1), inhibit apoptosis by
stimulating several intracellular signaling pathways, including
protein-tyrosine phosphorylation and activation of extracellu-
lar signal–regulated kinase (ERK)-1/2 and Akt (Parrizas et al.,
1997). In H9c2 cardiomyocytes, ghrelin induced tyrosine
phosphorylation of two intracellular proteins of 
 
 
 
100 and 60
kD, suggesting that it may activate a protein-tyrosine kinase
(Fig. 3 A). Similar results were obtained in PAE cells (unpub-
lished data). Ghrelin activated both ERK1/2 and Akt in
H9c2 cardiomyocytes (Fig. 3, B and C) and in endothelial
cells (unpublished data). Activation of ERK1/2 and Akt, mea-
sured as serine residue-specific phosphorylation, occurred as
early as 2 min after ghrelin stimulation, peaked between 5
and 10 min, and lasted at least 30 min. These data suggest
that early activation of ERK1/2 and Akt may be involved in
the transduction of the antiapoptotic signaling triggered by
ghrelin. To verify such hypothesis, we have investigated
whether pharmacological inhibition of either ERK1/2 or Akt
impairs ghrelin cytoprotective activity after doxorubicin treat-
ment. Activation of Akt was prevented by inhibition of
phosphatidylinositol (PI) 3-kinase, whose enzymatic product
PI(3,4,5)P
 
3
 
 mediates growth factor–induced activation of Akt
(Alessi et al., 1996; unpublished data). Cell treatment of both
H9c2 cardiomyocytes and PAE cells either with 30 
 
 
 
M
PD98059, a highly specific ERK1/2 inhibitor, or 100 nM
wortmannin, a highly specific inhibitor of PI 3-kinase, abol-
ished ghrelin’s cytoprotective activity after 20 h of treatment
with 1 
 
 
 
M doxorubicin (Fig. 3, D and E). Under these con-
ditions, neither PD98059 nor wortmannin affected doxoru-
bicin-induced cell death. Thus, these data suggest that ghrelin
inhibits cell death by activating at least two prosurvival signal-
ing pathways conveyed by ERK1/2 and PI 3-kinase/Akt.
 
Ghrelin and des-acyl ghrelin bind to a common 
receptor, distinct from GHSR-1a, and activate 
a common biochemical and biological response 
in H9c2 cardiomyocytes
 
Although GHSR-1a is expressed in the heart, proof that it
mediates ghrelin cardioprotective activity is still lacking. We
have assayed the expression of GHSR-1a in H9c2 cardiomyo-
cytes compared with the whole heart and the pituitary. Ex-
pression was measured by RT-PCR of GHSR-1a second
exon as described previously (Nagaya et al., 2001a). To our
surprise, no expression was detected in H9c2 cardiomyo-
Figure 2. Ghrelin and des-acyl ghrelin inhibit apoptosis. (A) Primary 
cultures of adult cardiomyocytes were pretreated with either 0.1, 
0.5, or 1  M ghrelin for 16 h. Then FAS was stimulated (black bars), 
and sub-G1 cells were measured by FACS
® analysis after 6 h. Data 
were calculated as the percentage of apoptotic nuclei induced by 
FAS stimulation above untreated control. Values are the mean   SE 
of three independent experiments (*t test, P   0.01). H9c2 
cardiomyocytes (B) and PAE cells (C) cultured in either 10% FCS 
(white bar) or 0% FCS (hatched bars) were pretreated with 1  M 
ghrelin or des-acyl ghrelin for 48 h. Apoptosis was measured by 
FACS
® analysis with fluorescent annexin V; values are mean   SE 
of three samples (*t test, P   0.02). 
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cytes, whereas a positive signal was detected from both the
whole heart and the pituitary (Fig. 4). Thus, these data sug-
gest that GHSR-1a is not expressed in H9c2 cardiomyocytes
and raise the hypothesis that ghrelin antiapoptotic activity
may not be mediated by GHSR-1a.
To further investigate the identity of the receptor mediat-
ing ghrelin antiapoptotic activity, we have performed bind-
ing studies of radio-labeled ghrelin to membranes of H9c2
cardiomyocytes. 
 
125
 
I-Tyr
 
4
 
-ghrelin recognized a single class of
high affinity, saturable, and specific binding sites (Fig. 5 A)
(
 
K
 
d
 
 
 
 
 
 4.0 
 
 
 
 0.9 nM; B
 
max
 
 
 
 
 
 20 
 
 
 
 1.8 fmol/mg protein;
data are the mean 
 
 
 
 SE of four separate experiments). The
binding of radio-labeled ghrelin was displaced by unlabeled
ghrelin and, surprisingly, though with lower affinity by des-
acyl ghrelin, the deacylated form of ghrelin, which does not
 
bind GHSR-1. The IC
 
50
 
 values for ghrelin and des-acyl
ghrelin were 8.1 
 
 
 
 1.0 nM and 22.5 
 
 
 
 1.5 nM, respectively
(Fig. 5 B and Table I). Consistently, 
 
125
 
I-Tyr
 
4
 
–des-acyl ghre-
lin recognized high affinity binding sites in H9c2 cardio-
myocytes (Fig. 5 C). Binding analysis demonstrated the exist-
ence of a single class of binding sites that show B
 
max
 
 (18.8 
 
 
 
1.4 fmol/mg protein) and 
 
K
 
d
 
 (4.6 
 
 
 
 0.60 nM) values very
close to those detected by radio-labeled ghrelin. In addition,
both unlabeled des-acyl ghrelin and ghrelin displaced bound
radio-labeled des-acyl ghrelin with IC
 
50
 
 values of 17.5 
 
 
 
 1.7
nM and 11.5 
 
 
 
 1.3 nM, respectively (Fig. 5 D and Table I).
A direct implication of these findings is that des-acyl
ghrelin might also be biologically active on H9c2 cardio-
myocytes. Furthermore, the findings support our previous
hypothesis that a novel ghrelin receptor, distinct from
GHSR-1a, is expressed in these cells. Thus, we have assayed
des-acyl ghrelin-induced signaling and antiapoptotic activity
in H9c2 cardiomyocytes.
Des-acyl ghrelin significantly inhibited apoptosis induced
by serum withdrawal in both H9c2 and PAE (Fig. 2, B and
C), inhibited doxorubicin-induced cell death in both cell
lines (Fig. 6 A), and stimulated ERK-1/2 and Akt in H9c2
cardiomyocytes (Fig. 6, B and C). Together, these data
strongly suggest that ghrelin and des-acyl ghrelin stimulate
an antiapoptotic pathway through binding and activation of
a common receptor.
In an attempt to further characterize such receptor pharma-
cologically, we have investigated the ability of synthetic GHS
to recognize it and to activate antiapoptotic signaling path-
ways. Hexarelin and MK-0677, respectively, a peptidyl and a
nonpeptidyl GHS, displace the binding of both 
 
125
 
I-Tyr
 
4
 
-
ghrelin and 
 
125
 
I-Tyr
 
4
 
–des-acyl ghrelin with similar affinities
(Fig. 5, B and D). IC
 
50
 
 values are summarized in Table I.
Figure 3. Ghrelin stimulates protein-tyrosine phosphorylation and activates ERK1/2 and Akt. Overnight serum-starved H9c2 cells were 
stimulated with 1  M ghrelin and lysed at different times. Total lysates were analyzed by Western blot with antiphosphotyrosine antibodies 
(A), specific anti-phosphoERK1/2 antibodies (B, top) and anti-ERK1/2 antibodies (B, bottom), and specific anti-phosphoAkt antibodies (C, top) 
and anti-Akt antibodies (C, bottom). H9c2 cardiomyocytes (D) and PAE cells (E) were treated with 1  M doxorubicin for 20 h (black bars) in 
the presence or absence of 1  M ghrelin and in the presence or absence of 100 nM wortmannin or 30  M PD98059. Cell death was measured 
by MTT assay. Values are the mean   SE of eight samples (*t test, P   0.01).
Figure 4. GHSr-1a is expressed in the whole heart but not in 
H9c2 cardiomyocytes. RT-PCR was performed on total RNA 
extracted from H9c2 cardiomyocytes and rat heart with primers 
specific for GHSR-1a (top) or GAPDH (bottom). 
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Consistent with the binding data, both hexarelin and MK-
0677 inhibited doxorubicin-induced cell death of H9c2 car-
diomyocytes as observed by phase–contrast microscopy (Fig.
7 A) and measured by MTT assay (Fig. 7 B). Hexarelin and
MK-0677 inhibited doxorubicin apoptosis also in PAE en-
dothelial cells as measured by MTT assay (Fig. 7 B).
Furthermore, hexarelin and MK-0677 stimulate enzy-
matic activity of both ERK-1/2 and Akt in H9c2 cardio-
myocytes with similar time course and potency of ghrelin
and des-acyl ghrelin (Fig. 7, C and D). Together, the data
are consistent with previous observations that hexarelin fea-
tures cardioprotective activity in a GH-independent manner
(Locatelli et al., 1999; Tivesten et al., 2000).
 
Discussion
 
Ghrelin is a gastric acyl-peptidic hormone acting on the hy-
pothalamus and pituitary to induce GH release, food intake,
and adiposity (Kojima et al., 1999; Tschop et al., 2000; Na-
kazato et al., 2001). In addition to its endocrine activities,
Figure 5. H9c2 cardiomyocytes express a ghrelin receptor distinct from GHSR-1a. (A and C) Specific binding was determined by 
incubation of crude membranes with increasing concentrations (0.25–20 nM) of either radio-labeled ghrelin (A) or radio-labeled des-acyl 
ghrelin (C) in the presence or absence of 1  M unlabeled ghrelin (A) or unlabeled des-acyl ghrelin (C), respectively: total binding ( ), 
specific binding ( ), and nonspecific binding ( ). Data are the average of duplicate assay determinants. Similar results were obtained in at 
least two other independent experiments. (B and D) Displacement curves of radio-labeled ghrelin (B) or radio-labeled des-acyl ghrelin (D) 
binding by unlabeled ghrelin ( ), des-acyl ghrelin ( ), hexarelin ( ), and MK-0677 ( ). Displacement binding values are the mean   SE 
of four separate experiments.
 
Table I. 
 
IC
 
50
 
 for 125I-Tyr
 
4
 
-ghrelin and 
 
125
 
I-Tyr
 
4
 
–des-acyl ghrelin
IC50 (nM)
 
125
 
I-Tyr
4-ghrelin displacement
125I-Tyr
4–des-acyl ghrelin displacement
Ghrelin  8.1    1.0 11.5   1.3
Des-acyl ghrelin 22.5   1.5 17.5   1.7
Hexarelin 13.8   1.2 14.9   1.1
MK-0677 20.0   1.8 20.9   1.71034 The Journal of Cell Biology | Volume 159, Number 6, 2002
ghrelin and synthetic GHS protect heart function from ex-
perimentally induced cardiac heart failure in vivo (Locatelli
et al., 1999; Tivesten et al., 2000; King et al., 2001; Nagaya
et al., 2001b). However, the cellular and molecular mecha-
nisms underlying ghrelin cardioprotective activity are not
known. Based on these observations, we have raised the hy-
pothesis that ghrelin may feature a direct cytoprotective ac-
tivity toward myocardial cells by inhibiting cell death of
cardiomyocytes and endothelial cells. In the heart, anti-
apoptotic factors, such as IGF-1 and cardiotrophin-1
(CT-1), play a crucial role in maintaining cardiomyocytes
survival and myocardial function after ischemia- and pres-
sure overload–induced cardiomyopathies (Buerke et al.,
1995; Hirota et al., 1999). The data reported here showing
the ability of ghrelin to inhibit apoptosis induced by either
doxorubicin serum withdrawal or FAS activation suggest
that it may act as a survival factor in cardiomyocytes and en-
dothelial cells. The data also supports the hypothesis that
ghrelin may play a role in myocardial homeostasis.
Survival factors inhibit cell death by activating specific sig-
naling pathways, including stimulation of protein-tyrosine
phosphorylation and activation of ERK-1/2 and PI 3-kinase/
Akt, which then lead to the inhibition of the apoptotic sig-
naling cascade (Wu et al., 2000). We have shown that ghre-
lin stimulates tyrosine phosphorylation and activates ERK-1/
2 and Akt and that activation of each of the two pathways is
required for ghrelin-induced inhibition of apoptosis. Activa-
tion of ERK-1/2 by ghrelin was reported previously in
HepG2 cells, which express GHSR-1, although in these cells
ghrelin inhibits rather than activates Akt (Murata et al.,
2002). The receptor-mediating ghrelin intracellular signaling
and antiapoptotic activity is not known. Here we provide
three pieces of evidence suggesting that ghrelin antiapoptotic
activity is not mediated by GHSR-1a. (i) In contrast to the
whole heart, no expression of GHSR-1a was detected in
H9c2 cardiomyocytes by RT-PCR. (ii) Both ghrelin and its
deacylated form, des-acyl ghrelin, recognize a common high
affinity binding site, although only ghrelin and not des-acyl
ghrelin bind to GHSR-1a (Kojima et al., 1999). Further-
more, affinity constant of ghrelin binding sites on H9c2 car-
diomyocytes are  10-fold higher than affinity constant of
GHSR-1a as measured on pituitary and hypothalamus mem-
branes (Muccioli et al., 2001). (iii) Des-acyl ghrelin, which is
devoid of any GH-releasing activity even in vitro (Kojima et
al., 1999), is as effective as ghrelin in inhibiting apoptosis
and in activating intracellular signaling pathways, i.e., ERK-
1/2, Akt, and protein-tyrosine phosphorylation (unpub-
lished data). Thus, these findings suggest that ghrelin and
des-acyl ghrelin bind to a novel receptor, distinct from
GHSR-1a. The putative novel receptor is expected to be
highly similar to GHSR-1a, since it differs only in its lack of
ability to discriminate between the esterified and unesterified
ghrelin peptide. Moreover, the demonstration that two syn-
thetic ligands of GHSR-1a, hexarelin and MK-0677, bind
and activate the novel receptor provides further support to
the hypothesis that the two receptors are highly related.
Whether such receptor is encoded by alternative splicing
of GHSR-1 gene or by a distinct gene still remains to be de-
termined. GHSR-1b, a GHSR-1–truncated splicing variant,
although expressed in the heart, does not appear to be func-
Figure 6. Des-acyl ghrelin inhibits cell death and activates ERK1/2 and Akt in H9c2 cardiomyocytes and PAE. (A) H9c2 cardiomyocytes 
and PAE cells were treated with 1  M doxorubicin (grey bar) for 24 h in the presence or absence of either 1  M ghrelin or des-acyl ghrelin. 
Cell death was assessed by the MTT assay. Values are mean   SE of eight samples (*t test, P   0.01). (B and C) H9c2 cardiomyocytes were 
serum starved overnight, stimulated with 1  M des-acyl ghrelin, and lysed at different times. Total lysates were analyzed by Western blot 
with specific anti-phosphoERK1/2 antibodies (B, top) and anti-ERK1/2 antibodies (B, bottom) and specific anti-phosphoAkt antibodies (C, top) 
and anti-Akt antibodies (C, bottom). Ghrelin and des-acyl ghrelin act as survival factors | Baldanzi et al. 1035
Figure 7. Hexarelin and MK-0677 inhibit cell death and activate ERK1/2 and Akt in H9c2 cardiomyocytes and PAE. (A) H9c2 cardiomyocytes 
were treated with 1  M of either doxorubicin, hexarelin, and/or MK-0677 as indicated. Phase–contrast images (200 ; bar, 0.1 mm) were 
captured after 24 h of treatment. Representative fields are shown. (B) H9c2 cardiomyocytes and PAE cells were treated with 1  M doxorubicin 
(grey bar) for 24 h in the presence or absence of either 1  M hexarelin or MK-0677. Cell death was assessed by the MTT assay. Values are 
mean   SE of eight samples (*t test, P   0.01). (C and D) H9c2 cardiomyocytes were serum starved overnight, stimulated with either 1  M 
hexarelin or MK-0677, and lysed at different times. Total lysates were analyzed by Western blot with specific anti-phosphoERK1/2 antibodies 
(C, top) and anti-ERK1/2 antibodies (C, bottom) and specific anti-phosphoAkt antibodies (D, top) and anti-Akt antibodies (D, bottom).
tional (Howard et al., 1996). We have reported previously
that both ghrelin and des-acyl ghrelin bind to a common re-
ceptor in breast cancer cells (Cassoni et al., 2001). In these
cells, ghrelin and des-acyl ghrelin inhibit cell proliferation,
whereas, on the other hand, GHSR-1a appears to mediate a
proliferative signal (Murata et al., 2002). Whether the same
ghrelin receptor mediates the inhibition of both growth and
apoptosis in breast cancer cells and in cardiomyocytes and
endothelial cells, respectively, it is not determined. Although
most survival factors also display a proliferative activity,
members of the transforming growth factor-  family inhibit
both cell growth and cell death in myoblasts (Chen et al.,
2001; Rios et al., 2001).
In addition, the finding that GHSR-1a is expressed in the
whole heart but not in H9c2 cardiomyocytes provides fur-
ther support to the hypothesis that multiple ghrelin recep-1036 The Journal of Cell Biology | Volume 159, Number 6, 2002
tors may be expressed in the cardiovascular system (Papotti
et al., 2000; Bodart et al., 2002; Gnanapavan et al., 2002;
Katugampola et al., 2001). Each receptor may then contrib-
ute independently to mediate the wide array of cardiovascu-
lar activities induced by both ghrelin and synthetic GHSs.
CD36, a fatty acid receptor, has been identified recently as a
myocardial receptor for hexarelin, a synthetic peptidyl GHS.
However, neither ghrelin nor the synthetic nonpeptidyl
GHS, MK-0677, recognize such receptor (Bodart et al.,
2002). Interestingly, similar hexarelin-binding sites, which
are not displaced by MK-0677, were also reported in H9c2
cardiomyocytes (Filigheddu et al., 2001).
In summary, the data presented here suggest that inhibi-
tion of apoptosis of cardiomyocytes and endothelial cells
may contribute to the reported cardioprotective activity of
ghrelin and of synthetic GHS in vivo. Ghrelin and des-acyl
ghrelin are active in vitro even at subnanomolar concentra-
tion, whereas their total serum concentration in the rat is
0.22   0.07 nM (Hosoda et al., 2000). In addition, these
data suggest that des-acyl ghrelin, which does not induce
GH release, may feature a cardioprotective activity in vivo.
Thus, we may speculate that the ghrelin gene product,
which is ubiquitously expressed, in addition to its endocrine
activity dependent on gastric release of its acylated form may
also be a trophic local factor acting in the cardiovascular sys-
tem in an autocrine/paracrine fashion.
Materials and methods
Cell cultures, chemicals, peptides, and reagents
H9c2 and PAE cells were obtained from American Type Culture Collection
and cultured as described previously (Cutrupi et al., 2000; Filigheddu et al.,
2001). Terminally differentiated cardiomyocytes were prepared from adult
guinea pig as described previously (Gallo et al., 2001). Ghrelin, des-acyl
ghrelin, radioiodinated Tyr
4-des-Phe
4-ghrelin (
125I-Tyr
4-ghrelin), and Tyr
4-
des-Phe
4–nonoctanoylated ghrelin (
125I-Tyr
4–des-acyl ghrelin) were pro-
vided by Europeptides. Antibodies were from cell signaling except 4G10
antiphosphotyrosine antibodies from UBI. Molecular biology reagents were
from GIBCO-BRL except Powerscript reverse transcriptase from CLON-
TECH Laboratories, Inc. and DyNAzyme EXT taq and PCR reagents from
Finzymes. Doxorubicin (Amersham Biosciences and Upjohn) was prepared
as a 1 mM solution in PBS and then sonicated and diluted to 1  M in 5%
FCS. Similar data were obtained when Doxorubicin was prepared in unbuf-
fered physiological solution and used without sonication at 0.1  M.
Cell death and apoptosis
Cells were plated in 96-well slides ( 25,000–30,000 cells/cm
2) for MTT
and LDH assays and in 10-cm dishes for other studies. Cell death was in-
duced by incubating the cells with 1  M doxorubicin in 5% FCS (H9c2) or
0% FCS (PAE) for the indicated time. FAS-mediated apoptosis of adult car-
diomyocytes was obtained by 30-min cell incubation on ice in the pres-
ence of 1  g/ml anti-FAS agonist antibodies (Bender MedSystem) and 1
 g/ml protein A (Sigma-Aldrich). Cells were then placed for 6 h at RT in ty-
rode medium as described previously (Gallo et al., 2001). Cell viability
was measured by MTT assay (Sigma-Aldrich) as described previously
(Filigheddu et al., 2001) and by Cytotoxicity Detection Kit (Roche), which
measures LDH released in the medium. Percentage cytotoxicity was calcu-
lated according to the manufacturer’s instructions. Apoptosis was evalu-
ated in H9c2 and PAE cells by FACS
® analysis (Becton Dickinson) of the
proportion of cells displaying shrunken/hypergranular morphology or
those stained with Annexin-V Fluos (Alexis) above the untreated controls.
Briefly, 0.5   10
5 cells were stained with annexin V (1:50) and 1  g/ml
propidium iodide in 10 mM Hepes-NaOH (pH 7.4), 140 mM NaCl, 5 mM
CaCl2, and incubated for 10–15 min at RT in the dark. Data were analyzed
by flow citometry software (Becton Dickinson). Apoptosis in adult cardio-
myocytes was detected as nucleosomal DNA fragmentation measured as
the percentage of sub-G1 cells. After treatment, cardiomyocytes were fixed
with ice-cold 70% ethanol, stored at  20 C overnight, and then incubated
for 10 min in phosphate-citric acid buffer at pH 7.8. Pelleted cells were
then stained with 1 ml of 25  g/ml propidium iodide, 400 mg/ml Rnase A,
and 1% Triton X-100 at RT for 15 min, and analyzed by FACS
®. The per-
centage of sub-G1 cells was calculated by CellFit software (Becton Dickin-
son) and defined as apoptotic. Direct microscopical observation confirmed
the presence of nuclear fragmentation and apoptotic bodies.
Western Blot and binding studies
Western blots of solubilized proteins were performed as described previ-
ously (Cutrupi et al., 2000). Binding of 
125I-Tyr
4-ghrelin and 
125I-Tyr
4–des-
acyl ghrelin to crude H9c2 cardiomyocytes membranes (30,000 g pellet)
and Scatchard analysis were determined as described previously (Muccioli
et al., 2001; Torsello et al., 2002). IC50 values of specific radioligand bind-
ing were determined by radiolabeled ghrelin and des-acyl ghrelin dis-
placement curves with increasing concentrations of unlabeled ghrelin and
des-acyl ghrelin. The maximal number of binding sites (Bmax) and the disso-
ciation constant (Kd) and IC50 values were calculated with the iterative
curve-fitting Prism3 program (GradPad Software, Inc.).
RT-PCR
Total RNA was extracted by Rneasy mini kit (QIAGEN) from either cul-
tured cells or rat heart and pituitary tissue mechanically triturated in liquid
nitrogen and retrotranscribed (1  g) in 20  l of RT-buffer in the presence
of 500 ng oligodT and 1  l Powerscript reverse transcriptase. Reverse tran-
scriptase reaction was performed at 42 C for 1.5 h and at 72 C for 15 min.
One fifth of the reverse transcriptase product (4  l of cDNA) was amplified
in 50  l PCR buffer (1  buffer, 1.5 mM MgCl2, 200  M dNTP, 1  M of
each primer, 1 U DyNAzyme EXT taq). PCR was performed by a 5-min in-
cubation at 95 C followed by 5 cycles (30 s at 94 C, 30 s at 55 C, and 3
min at 72 C) and 35 cycles (30 s at 94 C, 30 s at 60 C, and 3 min at 72 C).
Primers sequences for GHSR-1a were the rat homologues to the human se-
quences described previously by Nagaya et al. (2001a): 5 -CGGA-
GAGATGGGATGTGCTG-3  (forward) and 5 -CTCTGCTGGCTGCCCT-
TCCA-3  (reverse).
The authors wish to thank Prof. Paola Cassoni and Drs. Tiziana Marrocco,
Marianna Notario, Federica Chianale, and Marco Coscia for their partici-
pation in the study.
This study was supported by grants from University A. Avogadro of Pie-
monte Orientale and Regione Piemonte (to A. Graziani), Ministero
dell’Università e della Ricerca Scientifica e Tecnologica (1999 and 2000
to A. Graziani and to E. Ghigo), University of Torino (to A. Graziani, A. Fu-
bini, and E. Ghigo), Consiglio Nazionale delle Richerche (98.03040.CP04
to E. Ghigo and to F. Broglio), Fondazione per le Studio delle Malattie En-
docrino-Metaboliche, and Europeptides. G. Baldanzi was supported by a
fellowship from Fondazione Italiana per la Ricerca sul Cancro, and N.
Filigheddu was a recipient of the Ibsen/SIE award.
Submitted: 29 July 2002
Revised: 11 October 2002
Accepted: 21 October 2002
References
Alessi, D.R., M. Andjelkovic, B. Caudwell, P. Cron, N. Morrice, P. Cohen, and
B.A. Hemmings. 1996. Mechanism of activation of protein kinase B by in-
sulin and IGF-1. EMBO J. 15:6541–6551.
Arola, O.J., A. Saraste, K. Pulkki, M. Kallajoki, M. Parvinen, and L.M. Voipio-
Pulkki. 2000. Acute doxorubicin cardiotoxicity involves cardiomyocyte ap-
optosis. Cancer Res. 60:1789–1792.
Bisi, G., V. Podio, M.R. Valetto, F. Broglio, G. Bertuccio, G. Aimaretti, E. Pelosi,
G. Del Rio, G. Muccioli, H. Ong, et al. 1999. Cardiac effects of hexarelin in
hypopituitary adults. Eur. J. Pharmacol. 381:31–38.
Bodart, V., M. Febbraio, A. Demers, N. McNicoll, P. Pohankova, A. Perreault, T.
Sejlitz, E. Escher, R.L. Silverstein, D. Lamontagne, and H. Ong. 2002.
CD36 mediates the cardiovascular action of growth hormone-releasing pep-
tides in the heart. Circ. Res. 90:844–849.
Bowers, C.Y. 2001. Unnatural growth hormone-releasing peptide begets natural
ghrelin. J. Clin. Endocrinol. Metab. 86:1464–1469.
Buerke, M., T. Murohara, C. Skurk, C. Nuss, K. Tomaselli, and A.M. Lefer. 1995.
Cardioprotective effect of insulin-like growth factor I in myocardial ischemia
followed by reperfusion. Proc. Natl. Acad. Sci. USA. 92:8031–8035.
Cassoni, P., M. Papotti, C. Ghe, F. Catapano, A. Sapino, A. Graziani, R. De-
ghenghi, T. Reissmann, E. Ghigo, and G. Muccioli. 2001. Identification, Ghrelin and des-acyl ghrelin act as survival factors | Baldanzi et al. 1037
characterization, and biological activity of specific receptors for natural (ghre-
lin) and synthetic growth hormone secretagogues and analogs in human
breast carcinomas and cell lines. J. Clin. Endocrinol. Metab. 86:1738–1745.
Chen, S., D.C. Guttridge, E. Tang, S. Shi, K. Guan, and C.Y. Wang. 2001. Sup-
pression of tumor necrosis factor-mediated apoptosis by nuclear factor kap-
paB-independent bone morphogenetic protein/Smad signaling. J. Biol.
Chem. 276:39259–39263.
Cutrupi, S., G. Baldanzi, D. Gramaglia, A. Maffe, D. Schaap, E. Giraudo, W. van
Blitterswijk, F. Bussolino, P.M. Comoglio, and A. Graziani. 2000. Src-
mediated activation of alpha-diacylglycerol kinase is required for hepatocyte
growth factor-induced cell motility. EMBO J. 19:4614–4622.
Filigheddu, N., A. Fubini, G. Baldanzi, S. Cutrupi, C. Ghe, F. Catapano, F. Broglio,
A. Bosia, M. Papotti, G. Muccioli, et al. 2001. Hexarelin protects H9c2 cardio-
myocytes from doxorubicin-induced cell death. Endocrine. 14(1):113–119.
Gallo, M.P., D. Malan, I. Bedendi, C. Biasin, G. Alloatti, and R.C. Levi. 2001.
Regulation of cardiac calcium current by NO and cGMP-modulating
agents. Pflugers Arch. 441:621–628.
Gnanapavan, S., B. Kola, S.A. Bustin, D.G. Morris, P. McGee, P. Fairclough, S.
Bhattacharya, R. Carpenter, A.B. Grossman, and M. Korbonits. 2002. The
tissue distribution of the mRNA of ghrelin and subtypes of its receptor,
GHS-R, in humans. J. Clin. Endocrinol. Metab. 87:2988.
Hayakawa, K., G. Takemura, M. Koda, Y. Kawase, R. Maruyama, Y. Li, S. Mi-
natoguchi, T. Fujiwara, and H. Fujiwara. 2002. Sensitivity to apoptosis sig-
nal, clearance rate, and ultrastructure of fas ligand-induced apoptosis in in
vivo adult cardiac cells. Circulation. 105:3039–3045.
Hirota, H., J. Chen, U.A. Betz, K. Rajewsky, Y. Gu, J. Ross, Jr., W. Muller, and
K.R. Chien. 1999. Loss of a gp130 cardiac muscle cell survival pathway is a
critical event in the onset of heart failure during biomechanical stress. Cell.
97:189–198.
Hosoda, H., M, Kojima., H. Matsuo, and K. Kangawa. 2000. Ghrelin and des-acyl
ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Bio-
chem. Biophys. Res. Comm. 279:909–913.
Howard, A.D., S.D. Feighner, D.F. Cully, J.P. Arena, P.A. Liberator, C.I. Rosen-
blum, M. Hamelin, D.L. Hreniuk, O.C. Palyha, J. Anderson, et al. 1996. A
receptor in pituitary and hypothalamus that functions in growth hormone
release. Science. 273:974–977.
Inu, A. 2001. Ghrelin: an orexigenic and somatotrophic signal from the stomach.
Nat. Rev. Neurosci. 2:551–560.
Jeremias, I., C Kupatt, A. Martin-Villalba, H. Habazettl, J. Schenkel, P. Boekste-
gers, and K.M. Debatin. 2000. Involvement of CD95/Apo1/Fas in cell
death after myocardial ischemia. Circulation. 102:915–920.
Katugampola, S.D., Z. Pallikaros, and A.P. Davenport. 2001. [125I-His(9)]-ghre-
lin, a novel radioligand for localizing GHS orphan receptors in human and
rat tissue: up-regulation of receptors with athersclerosis. Br. J. Pharmacol.
134:143–149.
King, M.K., D.M. Gay, L.C. Pan, J.H. McElmurray, III, J.W. Hendrick, C. Pirie,
A. Morrison, C. Ding, R. Mukherjee, and F.G. Spinale. 2001. Treatment
with a growth hormone secretagogue in a model of developing heart failure:
effects on ventricular and myocyte function. Circulation. 103:308–313.
Kojima, M., H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa.
1999. Ghrelin is a growth-hormone-releasing acylated peptide from stom-
ach. Nature. 402:656–660.
Locatelli, V., G. Rossoni, F. Schweiger, A. Torsello, V. De Gennaro Colonna, M.
Bernareggi, R. Deghenghi, E.E. Muller, and F. Berti. 1999. Growth hor-
mone-independent cardioprotective effects of hexarelin in the rat. Endocri-
nology. 140:4024–4031.
Muccioli, G., M. Papotti, V. Locatelli, E. Ghigo, and R. Deghenghi. 2001. Bind-
ing of 
125I-labeled ghrelin to membranes from human hypothalamus and pi-
tuitary gland. J. Endocrinol. Invest. 24:RC7–RC9.
Muccioli, G., M. Tschöp, M. Papotti, R. Deghenghi, M. Heiman, and E. Ghigo.
2002. Neuroendocrine and peripheral activities of ghrelin: implications in
metabolism and obesity. Eur. J. Pharmacol. 440:235–254.
Murata, M., Y. Okimura, K. Iida, M. Matsumoto, H. Sowa, H. Kaji, M. Kojima, K.
Kangawa, and K. Chihara. 2002. Ghrelin modulates the downstream mole-
cules of insulin signaling in hepatoma cells. J. Biol. Chem. 277:5667–5674.
Nagaya, N., M. Kojima, M. Uematsu, M. Yamagishi, H. Hosoda, H. Oya, Y. Ha-
yashi, and K. Kangawa. 2001a. Hemodynamic and hormonal effects of hu-
man ghrelin in healthy volunteers. Am. J. Physiol. Regul. Integr. Comp. Phys-
iol. 280:R1483–R1487.
Nagaya, N., M. Uematsu, M. Kojima, Y. Ikeda, F. Yoshihara, W. Shimizu, H. Ho-
soda, Y. Hirota, H. Ishida, H. Mori, and K. Kangawa. 2001b. Chronic ad-
ministration of ghrelin improves left ventricular dysfunction and attenuates
development of cardiac cachexia in rats with heart failure. Circulation. 104:
1430–1435.
Nakamura, T., Y. Ueda, Y. Juan, S. Katsuda, H. Takahashi, and E. Koh. 2000.
Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in
vivo study. Circulation. 102:572–578.
Nakazato, M., N. Murakami, Y. Date, M. Kojima, H. Matsuo, K. Kangawa, and S.
Matsukura. 2001. A role for ghrelin in the central regulation of feeding. Na-
ture. 409:194–198.
Okumura, H., N. Nagaya, M. Enomoto, E. Nakagawa, H. Oya, and K. Kangawa.
2002. Vasodilatory effect of ghrelin, an endogenous peptide from the stom-
ach. J. Cardiovasc. Pharmacol. 39:779–783.
Papotti, M., C. Ghe, P. Cassoni, F. Catapano, R. Deghenghi, E. Ghigo, and G.
Muccioli. 2000. Growth hormone secretagogue binding sites in peripheral
human tissues. J. Clin. Endocrinol. Metab. 85:3803–3807.
Parrizas, M., A.R. Saltiel, and D. LeRoith. 1997. IGF-1 inhibits apoptosis using
the phosphatidylinositol 3 -kinase and mitogen-activated protein kinase
pathways. J. Biol. Chem. 272:154–161.
Rios, R., I. Carneiro, V.M. Arce, and J. Devesa. 2001. Myostatin regulates cell survival
during C2C12 myogenesis. Biochem. Biophys. Res. Commun. 280:561–566.
Takemura, G., S. Kato, T. Aoyama, Y. Hayakawa, M. Kanoh, R. Maruyama, M.
Arai, K. Nishigaki, S. Minatoguchi, K. Fukuda, et al. 2001. Characterization
of ultrastructure and its relation with DNA fragmentation in Fas-induced
apoptosis of cultured cardiac myocytes. J. Pathol. 193:546–556.
Tivesten, A., E. Bollano, K. Caidahl, V. Kujacic, X.Y. Sun, T. Hedner, A. Hjalmar-
son, B.A. Bengtsson, and J. Isgaard. 2000. The growth hormone secreta-
gogue hexarelin improves cardiac function in rats after experimental myocar-
dial infarction. Endocrinology. 141:60–66.
Torsello, A., C. Ghè, E. Bresciani, F. Catapano, E. Ghigo, R. Deghenghi, V. Locatelli,
and G. Muccioli. 2002. Short ghrelin peptides neither displace ghrelin binding
in vitro nor stimulate GH release in vivo. Endocrinology. 143:1968–1971.
Tschop, M., D.L. Smiley, and M.L. Heiman. 2000. Ghrelin induces adiposity in
rodents. Nature. 407:908–913.
Wu, W., W.L. Lee, Y.Y. Wu, D. Chen, T.J. Liu, A. Jang, P.M. Sharma, and P.H.
Wang. 2000. Expression of constitutively active phosphatidylinositol
3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle
cells. J. Biol. Chem. 275:40113–40119.
Yamamura, T., H. Nakamura, T. Yamamoto, S. Umemoto, T. Fujii, N. Koba-
yashi, and M. Matsuzaki. 1999. Fas expression and apoptosis correlate with
cardiac dysfunction in patients with dilated cardiomyopathy. Jpn. Circ. J.
63:149–154.